Earlier, Williams said in a speech that "it's better to take preventative measures than to wait for disaster to unfold."The Fedread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
The country's Revolutionary Guards say they will soon releasePoliticsread more
The co-founder of the world's largest money manager advises investors to stay in stocks, saying that taking risk off the table is a mistake.Marketsread more
Market researcher James Bianco believes it's crucial to get a half point cut at the next Federal Reserve meeting.Trading Nationread more
Regional stability, oil prices and potential for war will all depend on what Iran does with its nuclear program in the event of the deal's termination.World Politicsread more
Boeing will take a nearly $5 billion charge in the second quarter to compensate 737 Max customers as the planes remain grounded.Airlinesread more
The world's largest asset manager missed profit estimates, as investment advisory and securities lending revenue fell and costs rose.Financeread more
If you are contemplating a semiconductor stock, think Micron, say Piper Jaffray's Craig Johnson and Joule Financial's Quint Tatro.Trading Nationread more
The base version of the sports car will punch out 495 horsepower, 40 more than the seventh-generation car and enough to launch it from 0 to 60 in "less than three seconds"...Autosread more
Eugene Scalia would replace Alex Acosta as U.S. secretary of labor. Acosta announced he would step down last week.World Politicsread more
Check out the companies making headlines in the premarket Friday:
Amazon — A U.K. regulator is looking into the e-commerce giant's investment in food-delivery start-up Deliveroo. The Competition and Markets Authority said Friday it has "reasonable grounds" for suspecting the two companies could "cease to be distinct. " This would give the regulator the authority to block Amazon's $575 million investment.
Qualcomm, Micron Technology — Chipmakers fell broadly in the premarket after Samsung warned its second-quarter earnings likely plunged more than 50% from the previous year. Samsung cited weak demand for memory chips for the grim guidance.
Alexion Pharmaceuticals — The company announced the European Commission approved marketing for ULTOMIRIS, a drug used to treat paroxysmal nocturnal hemoglobinuria in adults. The U.S. Food and Drug Administration approved Alexion's drug in December of last year.
Canopy Growth — The Globe and Mail reported that former co-CEO's Bruce Linton's departure came after clashes with Constellation Brands CEO Bill Newlands. The outlet reported, citing sources, that Constellation Brands tried exerting more control over the cannabis company ever since becoming its largest shareholder. This led to disagreements between the two executives, the paper said.
Karyopharm Therapeutics — Karyopharm announced in a conference call Wednesday afternoon that Xpovio, a drug aimed at treading refractory multiple myeloma, was approved by the Food and Drug Administration. The company also said its wholesale acquisition cost for would be $22,000 per month.